Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Saumya Das
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Dyrnamix
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Das is a co-founder of Dyrnamix and he has founders equity in the privately held company. The company is developing computational methods for analyzing extracellular RNA biomarkers to predict cardiovascular outcomes. The research project seeks to identify novel circulating miRNA signatures that can prognosticate susceptibility to arrhythmia/SCA and HF post-MI and to integrate these biomarkers into a digital PCR-based assay readily translatable into the clinic. The research may result in the discovery of new RNA biomarker signatures that may be of interest to the company. The institution determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI
The complications of a myocardial infarction (heart attack) such as heart failure and lethal arrhythmias lead to significant morbidity and mortality. Current tests to predict which patients are at risk of these complications are imperfect. We seek to develop novel blood tests to identify patients at risk of developing these complications so that they can be treated prophylactically.
Filed on November 13, 2017.
Tell us what you know about Saumya Das's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Saumya Das filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Saumya Das | Massachusetts General Hospital | Conflict of Interest | Dyrnamix | Value cannot be readily determined |
| Saumya Das | Massachusetts General Hospital | Conflict of Interest | LQT Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.